Loading
institutionsInstitution
Tennessee Oncology / Greco-Hainsworth Centers for Research
Large community oncology practice in Nashville, the founding clinical partner of Sarah Cannon Research Institute, whose myeloma research under Jesús Berdeja led early CAR-T trials.
Also called: Tennessee Oncology PLLCGreco-Hainsworth Centers for Research
Overview
Tennessee Oncology is one of the largest independent community oncology practices in the United States, with clinics across Middle Tennessee. It founded the Sarah Cannon Research Institute with HCA Healthcare in the 1990s, and its Greco-Hainsworth Centers for Research, named for the founders of that model, continue to run trials in the practice. Jesús Berdeja, its director of myeloma research, was a lead investigator of CARTITUDE-1, the trial that established ciltacabtagene autoleucel in relapsed multiple myeloma.
Location
Nashville, TN, US
Type
hospital
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#643 · 4 points (0 Newsweek + 0 NCI + 4 from 2 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-24.
Matched to Tennessee Oncology, including child institutions. 420 works · 14,158 citations · 63% open access · 24% clinical trials · 1% reviews.
Oncology works per year
1292022
1162023
682024
512025
562026
Most works
- Melissa Lynne Johnson62 works
- Erika Paige Hamilton53 works
- Ian W. Flinn43 works
- David Robert Spigel39 works
- Meredith Ann McKean25 works
- Alexander I. Spira22 works
- Manish R. Patel21 works
- Luis G Paz-Ares18 works
- Minal A. Barve16 works
- Byoung Chul Cho16 works
Most cited
- Community oncology
- Myeloma cell therapy trials
- Early-phase trials
Similar pages
- TrialCARTITUDE-1
Shares Jesús G. Berdeja, Multiple myeloma.
- Key paperCARTITUDE-1: cilta-cel, a BCMA CAR-T, in heavily pretreated myeloma
Shares Jesús G. Berdeja, Multiple myeloma.
- TreatmentCiltacabtagene autoleucel
Shares Jesús G. Berdeja, Multiple myeloma.